Dupilumab (Dupixent, Sanofi & Regeneron) works well in children with atopic dermatitis (AD) regardless of whether they have any type 2 co-morbid conditions, according to a new study in Advances in Therapy.
For the LIBERTY AD PRESCHOOL part B study, investigators evaluated children aged 6 months to 5 years with moderate-to-severe AD who had been treated with either dupilumab or a placebo. Researchers compared patients who had only atopic dermatitis to those who had atopic dermatitis plus additional “type 2” inflammatory diseases, such as asthma and allergies. Results showed that dupilumab improved atopic dermatitis signs and symptoms in both groups of patients. The overall safety was consistent with the known dupilumab safety profile.
“Many children suffer from multiple allergic conditions at the same time, so knowing that dupilumab can be used to safely and effectively treat their atopic dermatitis whether or not they have additional atopic diseases such as asthma or allergies is an important step forward,” says Mark Boguniewicz, MD, pediatric allergist and immunologist at National Jewish Health in Denver, CO, and lead author on the study, in a news release.
